Weight-based dosing strategy may affect immunotherapy outcomes, shows study

By | June 15, 2021
Overweight cancer patients receiving immunotherapy treatments live more than twice as long as lighter patients, but only when dosing is weight-based, according to a study by cancer researchers at UT Southwestern Medical Center.